FI924396A0 - Diagnostiska aemnen. - Google Patents

Diagnostiska aemnen.

Info

Publication number
FI924396A0
FI924396A0 FI924396A FI924396A FI924396A0 FI 924396 A0 FI924396 A0 FI 924396A0 FI 924396 A FI924396 A FI 924396A FI 924396 A FI924396 A FI 924396A FI 924396 A0 FI924396 A0 FI 924396A0
Authority
FI
Finland
Prior art keywords
aemnen
diagnostic
imaging
diagnosis
functional
Prior art date
Application number
FI924396A
Other languages
English (en)
Other versions
FI924396A (fi
Inventor
Jo Klaveness
Thorfinn Ege
Scott M Rocklage
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of FI924396A0 publication Critical patent/FI924396A0/fi
Publication of FI924396A publication Critical patent/FI924396A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/806—Electrical property or magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Degasification And Air Bubble Elimination (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Amplifiers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hard Magnetic Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Soft Magnetic Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
FI924396A 1990-04-02 1992-09-30 Diagnostiska aemnen FI924396A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909007408A GB9007408D0 (en) 1990-04-02 1990-04-02 Compositions
PCT/EP1991/000619 WO1991015243A1 (en) 1990-04-02 1991-03-30 Diagnostic agents

Publications (2)

Publication Number Publication Date
FI924396A0 true FI924396A0 (fi) 1992-09-30
FI924396A FI924396A (fi) 1992-09-30

Family

ID=10673735

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924396A FI924396A (fi) 1990-04-02 1992-09-30 Diagnostiska aemnen

Country Status (17)

Country Link
US (3) US5384109A (fi)
EP (2) EP0727224A3 (fi)
JP (1) JPH06507371A (fi)
KR (1) KR100217208B1 (fi)
AT (1) ATE139449T1 (fi)
AU (1) AU655175B2 (fi)
CA (1) CA2079688A1 (fi)
DE (1) DE69120403T2 (fi)
DK (1) DK0523116T3 (fi)
ES (1) ES2088492T3 (fi)
FI (1) FI924396A (fi)
GB (1) GB9007408D0 (fi)
GR (1) GR3020563T3 (fi)
HU (1) HUT62489A (fi)
NO (1) NO923821L (fi)
RU (1) RU2102082C1 (fi)
WO (1) WO1991015243A1 (fi)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612019A (en) * 1988-12-19 1997-03-18 Gordon, Deceased; David Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles
GB9120508D0 (en) * 1991-09-26 1991-11-06 Nycomed As Diagnostic agents
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
US5494035A (en) * 1994-10-26 1996-02-27 Wisconsin Alumni Research Foundation Method for detecting presence of ferromagnetic objects in a medical patient
DE19503664C2 (de) * 1995-01-27 1998-04-02 Schering Ag Magnetorelaxometrische Detektion von Analyten
DE19508772C2 (de) * 1995-03-01 1998-01-29 Schering Ag Verfahren und Verbindungen zur Detektion von Analyten mittels Remanenzmessung und deren Verwendung
US5842986A (en) 1995-08-16 1998-12-01 Proton Sciences Corp. Ferromagnetic foreign body screening method and apparatus
GB9619758D0 (en) * 1996-09-23 1996-11-06 Nycomed Imaging As Method
US6965792B2 (en) * 1996-06-25 2005-11-15 Mednovus, Inc. Susceptometers for foreign body detection
US7047059B2 (en) * 1998-08-18 2006-05-16 Quantum Magnetics, Inc Simplified water-bag technique for magnetic susceptibility measurements on the human body and other specimens
US20020115925A1 (en) * 1996-06-25 2002-08-22 Avrin William F. Ferromagnetic foreign body detection utilizing eye movement
US6496713B2 (en) 1996-06-25 2002-12-17 Mednovus, Inc. Ferromagnetic foreign body detection with background canceling
ES2237146T3 (es) 1998-08-28 2005-07-16 Destiny Pharma Limited Derivados de porfirina, su uso en terapia fotodinamica y dispositivos medicos que los contienen.
DE10046514A1 (de) * 2000-09-15 2002-04-25 Diagnostikforschung Inst Verfahren zur bildlichen Darstellung und Diagnose von Thromben mittels Kernspintomographie unter Verwendung partikulärer Kontrastmittel
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
DE10151778A1 (de) 2001-10-19 2003-05-08 Philips Corp Intellectual Pty Verfahren zur Ermittlung der räumlichen Verteilung magnetischer Partikel
US20030083588A1 (en) * 2001-10-29 2003-05-01 Mcclure Richard J. Pre-screening utilizing magnetic resonance imaging field
US20030216632A1 (en) * 2001-10-29 2003-11-20 Mednovus, Inc. Ferromagnetic sensing method and apparatus
FR2848750B1 (fr) * 2002-12-13 2007-02-09 Centre Nat Rech Scient Procede d'acquisition de signaux electromagnetiques et produit de contraste pour une telle acquisition
EP1614694A4 (en) * 2003-03-31 2008-11-05 Toto Ltd TITANIUM DIOXIDE COMPLEX HAVING A RECONNAISSABLE MOLECULE
US20050261763A1 (en) * 2003-04-08 2005-11-24 Xingwu Wang Medical device
US20050244337A1 (en) * 2003-04-08 2005-11-03 Xingwu Wang Medical device with a marker
US20050240100A1 (en) * 2003-04-08 2005-10-27 Xingwu Wang MRI imageable medical device
US20050278020A1 (en) * 2003-04-08 2005-12-15 Xingwu Wang Medical device
US20060248944A1 (en) * 2003-04-15 2006-11-09 Koninklijke Philips Electronics N.V. Method to determine the spatial distribution of magnetic particles and magnetic particle administering compositions
US20070027532A1 (en) * 2003-12-22 2007-02-01 Xingwu Wang Medical device
US8118754B1 (en) 2007-11-15 2012-02-21 Flynn Edward R Magnetic needle biopsy
US7309316B1 (en) 2004-03-01 2007-12-18 Flynn Edward R Magnetic needle biopsy
US9964469B2 (en) 2005-02-28 2018-05-08 Imagion Biosystems, Inc. Magnetic needle separation and optical monitoring
WO2006099255A2 (en) * 2005-03-10 2006-09-21 Gen-Probe Incorporated Systems and methods to perform assays for detecting or quantifying analytes within samples
WO2006122203A1 (en) * 2005-05-11 2006-11-16 The University Of Houston System An intraluminal magneto sensor system and method of use
WO2006122202A1 (en) * 2005-05-11 2006-11-16 The University Of Houston System An intraluminal mutlifunctional sensor system and method of use
US20090295385A1 (en) * 2005-05-11 2009-12-03 Audrius Brazdeikis Magneto Sensor System and Method of Use
EP2062039A4 (en) * 2006-09-01 2012-05-02 Commw Scient Ind Res Org METHOD AND APPARATUS FOR RECOVERING THE SIGNAL
US8447379B2 (en) 2006-11-16 2013-05-21 Senior Scientific, LLC Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
GB0907372D0 (en) 2009-04-29 2009-06-10 Invitrogen Dynal As Particles
US8666473B2 (en) * 2009-04-30 2014-03-04 Koninklijke Philips N.V. Arrangement and method for influencing and/or detecting magnetic particles and for magnetic resonance imaging
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
US10194825B2 (en) 2009-11-06 2019-02-05 Imagion Biosystems Inc. Methods and apparatuses for the localization and treatment of disease such as cancer
JP5805651B2 (ja) * 2009-11-06 2015-11-04 サイエンティフィック ナノメディスン, インコーポレイテッドScientific Nanomedicine, Inc. 標的ナノ粒子及びその磁性粒子を使用する癌等の細胞及び他の生物学的物質の検出、測定、及び撮像
US8970217B1 (en) 2010-04-14 2015-03-03 Hypres, Inc. System and method for noise reduction in magnetic resonance imaging
EP2648806B1 (en) * 2010-12-08 2015-02-18 Elekta AB (publ) Radiotherapeutic apparatus
AU2014228815B2 (en) 2013-03-15 2019-04-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
EP2786768A1 (en) * 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
US10088336B2 (en) 2016-01-21 2018-10-02 Lockheed Martin Corporation Diamond nitrogen vacancy sensed ferro-fluid hydrophone
US10338162B2 (en) 2016-01-21 2019-07-02 Lockheed Martin Corporation AC vector magnetic anomaly detection with diamond nitrogen vacancies
US9817081B2 (en) 2016-01-21 2017-11-14 Lockheed Martin Corporation Magnetometer with light pipe
US10088452B2 (en) 2016-01-12 2018-10-02 Lockheed Martin Corporation Method for detecting defects in conductive materials based on differences in magnetic field characteristics measured along the conductive materials
US9638821B2 (en) 2014-03-20 2017-05-02 Lockheed Martin Corporation Mapping and monitoring of hydraulic fractures using vector magnetometers
US9910104B2 (en) 2015-01-23 2018-03-06 Lockheed Martin Corporation DNV magnetic field detector
US10006973B2 (en) 2016-01-21 2018-06-26 Lockheed Martin Corporation Magnetometer with a light emitting diode
US9853837B2 (en) 2014-04-07 2017-12-26 Lockheed Martin Corporation High bit-rate magnetic communication
US9910105B2 (en) 2014-03-20 2018-03-06 Lockheed Martin Corporation DNV magnetic field detector
US9824597B2 (en) 2015-01-28 2017-11-21 Lockheed Martin Corporation Magnetic navigation methods and systems utilizing power grid and communication network
US20170068012A1 (en) * 2015-09-04 2017-03-09 Lockheed Martin Corporation Magnetic wake detector
US10168393B2 (en) 2014-09-25 2019-01-01 Lockheed Martin Corporation Micro-vacancy center device
US10120039B2 (en) 2015-11-20 2018-11-06 Lockheed Martin Corporation Apparatus and method for closed loop processing for a magnetic detection system
US9835693B2 (en) 2016-01-21 2017-12-05 Lockheed Martin Corporation Higher magnetic sensitivity through fluorescence manipulation by phonon spectrum control
GB2540308B (en) 2014-04-07 2018-05-16 Lockheed Corp Energy efficient controlled magnetic field generator circuit
AU2015292498B2 (en) 2014-07-23 2020-11-05 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
RU2570768C1 (ru) * 2014-11-25 2015-12-10 Федеральное государственное бюджетное учреждение науки Институт физиологии им. И.П. Павлова Российской академии наук (ИФ РАН) Способ бесконтактного магнитометрического исследования физического состояния внутренних структур человека или животного
KR20170108055A (ko) 2015-01-23 2017-09-26 록히드 마틴 코포레이션 자기 검출 시스템에서의 고감도 자력 측정 및 신호 처리를 위한 장치 및 방법
EP3251193A4 (en) 2015-01-28 2018-08-08 Lockheed Martin Corporation In-situ power charging
GB2550809A (en) 2015-02-04 2017-11-29 Lockheed Corp Apparatus and method for estimating absolute axes' orientations for a magnetic detection system
GB2551090A (en) 2015-02-04 2017-12-06 Lockheed Corp Apparatus and method for recovery of three dimensional magnetic field from a magnetic detection system
EP3371614A1 (en) 2015-11-04 2018-09-12 Lockheed Martin Corporation Magnetic band-pass filter
WO2017087014A1 (en) 2015-11-20 2017-05-26 Lockheed Martin Corporation Apparatus and method for hypersensitivity detection of magnetic field
WO2017095454A1 (en) 2015-12-01 2017-06-08 Lockheed Martin Corporation Communication via a magnio
EP3405603A4 (en) 2016-01-21 2019-10-16 Lockheed Martin Corporation DIAMOND NITROGEN SENSOR WITH SWITCHING ON DIAMOND
WO2017127096A1 (en) 2016-01-21 2017-07-27 Lockheed Martin Corporation Diamond nitrogen vacancy sensor with dual rf sources
WO2017127095A1 (en) 2016-01-21 2017-07-27 Lockheed Martin Corporation Diamond nitrogen vacancy sensor with common rf and magnetic fields generator
US10330744B2 (en) 2017-03-24 2019-06-25 Lockheed Martin Corporation Magnetometer with a waveguide
US20170343621A1 (en) 2016-05-31 2017-11-30 Lockheed Martin Corporation Magneto-optical defect center magnetometer
US10527746B2 (en) 2016-05-31 2020-01-07 Lockheed Martin Corporation Array of UAVS with magnetometers
US10345395B2 (en) 2016-12-12 2019-07-09 Lockheed Martin Corporation Vector magnetometry localization of subsurface liquids
US10338163B2 (en) 2016-07-11 2019-07-02 Lockheed Martin Corporation Multi-frequency excitation schemes for high sensitivity magnetometry measurement with drift error compensation
US10281550B2 (en) 2016-11-14 2019-05-07 Lockheed Martin Corporation Spin relaxometry based molecular sequencing
US10371765B2 (en) 2016-07-11 2019-08-06 Lockheed Martin Corporation Geolocation of magnetic sources using vector magnetometer sensors
US10408890B2 (en) 2017-03-24 2019-09-10 Lockheed Martin Corporation Pulsed RF methods for optimization of CW measurements
US10274550B2 (en) 2017-03-24 2019-04-30 Lockheed Martin Corporation High speed sequential cancellation for pulsed mode
US10228429B2 (en) 2017-03-24 2019-03-12 Lockheed Martin Corporation Apparatus and method for resonance magneto-optical defect center material pulsed mode referencing
US10359479B2 (en) 2017-02-20 2019-07-23 Lockheed Martin Corporation Efficient thermal drift compensation in DNV vector magnetometry
US10677953B2 (en) 2016-05-31 2020-06-09 Lockheed Martin Corporation Magneto-optical detecting apparatus and methods
US10145910B2 (en) 2017-03-24 2018-12-04 Lockheed Martin Corporation Photodetector circuit saturation mitigation for magneto-optical high intensity pulses
US10345396B2 (en) 2016-05-31 2019-07-09 Lockheed Martin Corporation Selected volume continuous illumination magnetometer
US10317279B2 (en) 2016-05-31 2019-06-11 Lockheed Martin Corporation Optical filtration system for diamond material with nitrogen vacancy centers
US10571530B2 (en) 2016-05-31 2020-02-25 Lockheed Martin Corporation Buoy array of magnetometers
US10338164B2 (en) 2017-03-24 2019-07-02 Lockheed Martin Corporation Vacancy center material with highly efficient RF excitation
US10459041B2 (en) 2017-03-24 2019-10-29 Lockheed Martin Corporation Magnetic detection system with highly integrated diamond nitrogen vacancy sensor
US10379174B2 (en) 2017-03-24 2019-08-13 Lockheed Martin Corporation Bias magnet array for magnetometer
US10371760B2 (en) 2017-03-24 2019-08-06 Lockheed Martin Corporation Standing-wave radio frequency exciter
EP3412303A1 (en) 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
US11136543B1 (en) 2020-02-11 2021-10-05 Edward R. Flynn Magnetic cell incubation device

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079730A (en) * 1974-10-02 1978-03-21 The Board Of Trustees Of The Leland Stanford Junior University Apparatus for measuring externally of the human body magnetic susceptibility changes
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
SE463651B (sv) * 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
US5087438A (en) * 1984-07-03 1992-02-11 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
US4687658A (en) * 1984-10-04 1987-08-18 Salutar, Inc. Metal chelates of diethylenetriaminepentaacetic acid partial esters for NMR imaging
US5073858A (en) * 1984-12-10 1991-12-17 Mills Randell L Magnetic susceptibility imaging (msi)
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4730066A (en) * 1986-05-06 1988-03-08 Mallinckrodt, Inc. Complex for enhancing magnetic resonance imaging
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4813399A (en) * 1986-07-18 1989-03-21 Gordon Robert T Process for the treatment of neurological or neuromuscular diseases and development
US4996991A (en) * 1986-07-18 1991-03-05 Gordon Robert T Method for following the distribution of particles in neurological or neuromuscular tissue and cells
WO1988006605A1 (en) * 1987-02-27 1988-09-07 General Electric Company Macrocyclic oligomers containing spiro(bis)indane moieties
WO1990007322A1 (en) * 1988-12-19 1990-07-12 David Gordon Diagnosis and treatment of viral effects
US4951674A (en) * 1989-03-20 1990-08-28 Zanakis Michael F Biomagnetic analytical system using fiber-optic magnetic sensors

Also Published As

Publication number Publication date
US5384109A (en) 1995-01-24
GB9007408D0 (en) 1990-05-30
ES2088492T3 (es) 1996-08-16
ATE139449T1 (de) 1996-07-15
DE69120403T2 (de) 1996-10-31
HU9203127D0 (en) 1992-12-28
EP0523116A1 (en) 1993-01-20
GR3020563T3 (en) 1996-10-31
DK0523116T3 (da) 1996-07-15
EP0523116B1 (en) 1996-06-19
NO923821D0 (no) 1992-10-01
EP0727224A2 (en) 1996-08-21
WO1991015243A1 (en) 1991-10-17
EP0727224A3 (en) 1997-07-09
RU2102082C1 (ru) 1998-01-20
AU655175B2 (en) 1994-12-08
HUT62489A (en) 1993-05-28
JPH06507371A (ja) 1994-08-25
CA2079688A1 (en) 1991-10-03
FI924396A (fi) 1992-09-30
KR930700161A (ko) 1993-03-13
DE69120403D1 (de) 1996-07-25
KR100217208B1 (ko) 1999-09-01
US5628983A (en) 1997-05-13
US5738837A (en) 1998-04-14
NO923821L (no) 1992-11-19
AU7565591A (en) 1991-10-30

Similar Documents

Publication Publication Date Title
FI924396A (fi) Diagnostiska aemnen
DK528385A (da) Kontrastmidler
DE3577185D1 (de) Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
NO175364C (no) Fysiologisk forenlige amidkomplekser, diagnostiske midler og anvendelse derav
ATE342738T1 (de) Kontrastmittel für diagnostische bildgebung mit verlängerter verweilzeit im blut
NO874971L (no) Forbedret metallholdig diagnostisk middel.
FI98988B (fi) Varjoaineita
DE69434618D1 (de) Tricyclopolyazamacrocyclophosphonsäuren, ihre komplexe und derivate, für eine verwendung als kontrastmittel
HK1000311A1 (en) Hepatobiliary nmr contrast agents
NO177625C (no) Diagnostisk hjelpemiddel samt testkit omfattende hjelpemiddelet
FI954499A (fi) Menetelmä ja analyysi
Ames Arnold Gesell: Themes of his work.
NL193915B (nl) Apparaat voor het onderzoeken van een lichaam door magnetische kernresonantie en toepassing bij het afbeelden van de menselijke huid.
ATE167665T1 (de) Hydroxamat- und hydrazidderivate von polyaminen und ihre medizinische verwendung als chelatierende wirkstoffe
BR9508435A (pt) Quelentes macrocíclicos seus quelatos e usos dos mesmos no campo diagnóstico
BR1101072A (pt) Complexos paramagnéticos de dtpa e edta de alquoxialquil amida como agentes mri.
ITMI932728A1 (it) Formulazioni diagnostiche paramagnetiche e metodo d'uso delle stesse
DE69637715D1 (de) Synthetische säugetier alpha-n-acetylglukosaminidase und dafür kodierende genetische sequenzen
NO883626D0 (no) Fremgangsmaate for diagnose av kikhoste og testsett for utfoerelse av fremgangsmaaten.
FR2556958B1 (fr) Appareil de detection, diagnostic et soins suivant l'acupuncture magnetique et bio-magnetique
DE59510686D1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
ATE52032T1 (de) Paramagnetische kontrastmittel fuer die anwendung in ''in vivo'' nmr-diagnostischen methoden und die herstellung davon.
ATA187691A (de) Diagnostisches mittel, insbesondere zur diagnose von chronischer polyarthritis
FR2623317B1 (fr) Dispositif simulant l'action du coeur destine a diverses applications dans le cadre du diagnostic medical
NO874986D0 (no) Lysinsalt av gadolinium dota-kompleks og anvendelse derav for diagnose.